Sunshine Heart Announces Presentations at the Annual Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

By GlobeNewswire,  May 14, 2014, 05:30:00 AM EDT

EDEN PRAIRIE, Minn., May 14, 2014 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (Nasdaq:SSH) today announced that Dr. Patrick Verta, Sunshine Heart's Chief Medical Officer, will be presenting two posters at the Annual Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), May 17-20 at the Megaron Athens International Conference Centre in Athens, Greece.

Additional information on the poster presentations can be found below and posters can be accessed at following the presentations on May 17th.

Poster Presentations:  
Date/Time: Saturday, May 17, 2014, 8:30 AM - 6:00 PM
Location: Poster Area
Session Title: Poster with discussant session
Presentation Title: Preliminary results from the C-Pulse® System European Multicenter Study
Authors: Holger Hotz, MD, Leonhard Bruch, MD, Jan Schmitto, MD, Thomas Krabatsch, MD
Abstract Number: P256
Date/Time: Saturday, May 17, 2014, 8:30 AM - 6:00 PM
Location: Poster Area
Session Title: Poster with discussant session
Presentation Title: Improvements in Myocardial Perfusion Observed in Patients Supported with the C-Pulse® Counterpulsation Device
Authors: Renzo Cecere, MD, Marc Hickeson, MD, Nadia Giannetti, MD
Abstract Number: P260

About the C-Pulse® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System will be able to stop using the device due to sustained improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.

About Sunshine® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study.  In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe.  Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland.  The Company has been listed on the NASDAQ Capital Market since February 2012.  

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management.  All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption "Risk Factors" and elsewhere in our filings with the SEC.  You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

CONTACT: For further information, please contact:

         Candice KnollBlueprint Life Science Group
         T: +1-415-375-3340 Ext. 105

         Jeff Mathiesen
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200

         David SchullRusso Partners
         T: +1-212-845-4271

         Andreas Marathis
         Russo Partners
         T: +1-212-845-4235

Source: Sunshine Heart, Inc.

This article appears in: News Headlines

Referenced Stocks: SSH

Latest News Video

UN Calls for Ceasefire
UN Calls for Ceasefire              

Most Active by Volume

Company Last Sale Change Net / %
FB $ 75.19 0.21 ▲ 0.28%
SIRI $ 3.44 0.01 ▼ 0.29%
AAPL $ 97.671 0.64 ▲ 0.66%
F $ 17.62 0.22 ▼ 1.23%
BAC $ 15.59 0.03 ▼ 0.19%
AMAT $ 21.23 0.53 ▼ 2.41%
AMD $ 3.76 0.03 ▲ 0.80%
INTC $ 34.25 unch

As of 7/25/2014, 04:03 PM